FINWIRES · TerminalLIVE
FINWIRES

Turaco Gold Identifies Gold Mineralization at Ivory Coast Project

By

Turaco Gold (ASX:TCG) identified further mineralization from ongoing drilling at the Afema gold project in south-east Ivory Coast, according to a Tuesday Australian bourse filing.

The results were up to 28 meters at 2.17 grams per tonne gold (g/t) from 91 meters, including 15 meters at 3.32 g/t gold from 104 meters.

The company said the results are from resource extension and infill drilling on the Adiopan-Asupiri deposit, which hosts a current 1.32 million ounce mineral resource estimate (MRE) within the 4.65 million ounce Afema MRE.

Shallow drilling at the Sikasso prospect returned 21 meters at 2.29 g/t gold from 66 meters, with mineralization at both Bergerie and Sikasso occurring from surface and remaining open with further drilling underway, the filing added.

The Afema pre-feasibility study (PFS) is due in June, with five drill rigs currently operating with a focus on new discoveries, the company added.

Related Articles

Asia

Shenzhen LDROBOT Soars 103% in Hong Kong Trading Debut

Shenzhen LDROBOT's (HKG:1236) shares opened 102.9% above their initial public offering price in a stellar Hong Kong debut on Monday morning.The Chinese robotics company opened at HK$53.50 per share, well above the offer price of HK$26.36.

HKG:1236
Asia

Concord Healthcare to Issue HK$68 Million Convertible Bonds to CSPC Pharma Unit

Concord Healthcare (HKG:2453) agreed to issue HK$68 million of convertible bonds to a unit of CSPC Pharmaceutical (HKG:1093), according to a Monday Hong Kong bourse filing.The oncology healthcare service provider said Dragon Merit will subscribe to the 2% convertible bonds due in April 2027.The bonds are convertible into as many as 40 million Hong Kong-listed shares at an initial conversion price of HK$1.70 per share, representing a premium of about 14.1% to the stock's last closing price.Net proceeds of about HK$63.1 million will mainly be used to repay loans and supplement working capital.Concord Healthcare said the investment is expected to deepen cooperation with CSPC Pharmaceutical in the oncology healthcare sector.

HKG:1093HKG:2453
Asia

Alterity Therapeutics Says Peer-Reviewed Study Validates its Approach to Multiple System Atrophy; Shares Fall 9%

Alterity Therapeutics (ASX:ATH) said findings of a study published in the NeuroImage journal support quantitative susceptibility mapping as an objective imaging biomarker to facilitate the earlier diagnosis of multiple system atrophy (MSA), according to a Monday filing with the Australian bourse.Alterity is advancing its ATH434 lead candidate into a phase three program for multiple system atrophy, a neurodegenerative disease that leads to the failure of the autonomic nervous system and impaired movement.The company said it used quantitative susceptibility mapping in a phase two trial in which ATH434 helped improve diagnostic accuracy and provided "objective evidence of target engagement."The peer-reviewed publication validates the company's approach and "reinforces the role of [quantitative susceptibility mapping] as a biomarker for iron-modulating therapies in MSA," Alterity CEO David Stamler said.The company's shares fell 9% in recent Monday trade.

ASX:ATH